Precision Medicine
This year's meeting kicked off with a session focused on precision medicine, an emerging area in which scientists and physicians are defining new strategies to customize treatments for patients with cardiovascular disease. Dr Dan Roden from Vanderbilt University opened the session by providing a view of precision medicine from the clinic. An area of discussion was phenome-wide association studies, through which one can analyze many phenotypes of a single genetic variant and link to cardiovascular outcomes. A follow-up to this talk considered personalized medical care in a discussion of pharmacogenomics. Dr Paul Gurbel from Ivona Heart and Vascular Institute discussed how a specific human single nucleotide polymorphism in CYP 2C19 affects drug responsiveness to clopidogrel, a P2Y 12 antagonist. At a molecular level, Dr Joseph Wu from Stanford University discussed the concept of precision medicine in a dish using induced pluripotent stem cells. The idea was that cells isolated from patient blood with cardiovascular disease can be reprogrammed into cells of interest to define the mechanism causing disease and to identify new strategies for therapeutic interventions. Finally, Dr Kiran Musumuru from the University of Pennsylvania led an interactive session in which the audience voted on a definition of precision medicine. The winning definition was "A clinical and scientific strategy to optimize patient care by individualizing diagnosis, treatment, and prognosis, facilitated by ongoing advances in molecular and clinical diagnostics." With the growing availability of genetic testing, patients are becoming more empowered to partake in their own healthcare decisions. Precision medicine will likely help guide future decisions for better heath care for individuals with cardiovascular disease.
No Longer "Junk" RNA Given this growing ability to detect genetic differences, many presentations at this year's meeting considered the use of deep sequencing and identification of the role of what was once considered "junk" RNA. Dr Stephanie Dimmeler from the Institute of Cardiovascular Regeneration in Frankfurt, Germany, presented the Keynote Lecture on "RNA Control in Vascular Biology: Implications for Atherosclerosis and Neovascularization." She highlighted the use of noncoding RNAs as potential targets in atherosclerosis, starting with microRNA miR-92a in the regulation of angiogenesis and endothelial cells before demonstrating that the long noncoding RNA MALAT1 (metastasis associated lung adenocarcinoma transcript 1) regulates endothelial proliferation and that a reduction in this long noncoding RNA augments atherosclerosis. Many other presentations throughout the meeting also discussed the emergence of these new markers as significant indicators of disease. Notably, the winner of the Irvine Page Award, Dr Elizabeth Tarling of the University of California, Los Angeles, and the winner of the Daniel Steinberg Early Career Award, Dr Mireille Ouimet of Ottawa Heart Institute, also demonstrated the role of microRNAs in atherosclerosis. Dr Tarling discussed miR-144's role in the regression of atherosclerosis and, specifically, differences in gender, and Dr Ouimet presented on macrophage autophagy and the involvement of miR-33. In addition, Dr Muredach Reilly of Columbia University introduced the role of long intergenic noncoding RNAs in modulating macrophage inflammatory and metabolic functions that affect complex cardiometabolic disease. Knowledge about the involvement of noncoding RNAs in cardiovascular disease is rapidly increasing and will provide a road map for interrogation of biological systems to predict potential treatment strategies.
The Aging Cell
A number of presentations addressed the concept of the aging blood vessel and the role of senescence and calcification in this process. Dr Catherine Shanahan of Kings College London described the role of programmed cell death and apoptosis in chronic kidney disease patients receiving dialysis and the associated vascular calcification that occurs. In addition, she presented data on the interaction of aging and vascular cell phenotype, addressing the nuclear lamina, or network of filament proteins, that is part of the cell nucleus. The aging vascular smooth muscle cell accumulates prelamin A, which leads to DNA damage and triggers the osteogenic phenotype switch, leading the vascular calcification. Dr Delphine Gomez of the University of Pittsburgh also addressed the epigenetic control of smooth muscle cells and how histone markers can maintain lineage memory. Abstract presentations also discussed senescence in other cells of the atherosclerotic plaque, such as macrophages and foam cells. Dr Elena Aikawa from Harvard Medical School, Brigham and Women's Hospital, presented advances she and 
